- Home
- SABA vs NERV Comparison
SABA vs NERV Comparison
Compare SABA & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SABA | NERV |
|---|---|---|
| Founded | 1988 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 227.3M | 210.1M |
| IPO Year | 1994 | 2014 |
Fundamental Metrics
Financial Performance| Metric | SABA | NERV |
|---|---|---|
| Price | $8.30 | $5.04 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.50 |
| AVG Volume (30 Days) | 50.0K | ★ 334.2K |
| Earning Date | 01-01-0001 | 05-01-2026 |
| Dividend Yield | ★ 12.91% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,175,600.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.96 | $1.63 |
| 52 Week High | $9.46 | $12.46 |
Technical Indicators
Market Signals| Indicator | SABA | NERV |
|---|---|---|
| Relative Strength Index (RSI) | 48.27 | 53.71 |
| Support Level | $8.20 | $5.02 |
| Resistance Level | $8.68 | $5.61 |
| Average True Range (ATR) | 0.11 | 0.47 |
| MACD | 0.01 | 0.14 |
| Stochastic Oscillator | 61.29 | 59.78 |
Price Performance
Historical ComparisonAbout SABA Saba Capital Income & Opportunities Fund II Shares of Beneficial Interest
Saba Capital Income & Opportunities Fund II is a closed-end fund. The company seeks high current income, with a secondary goal of capital appreciation. The fund invests in fixed income markets across the globe.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.